miCheckup. Reserve your test for $49 Lock in the $799 preorder price — reg. $1,299 · Limited supply $799 preorder · reg. $1,299 Reserve now →
miRoncol Health

Family Doctors

Family Doctors & Integrative Medicine Practitioners

Supporting proactive patients with meaningful molecular insight.

Family doctors are often the first point of contact for patients concerned about cancer prevention. While conventional screening guidelines remain essential, many patients are seeking additional ways to understand their risk.

The miRoncol Real-time Multi-Cancer Early Risk Assessment provides a blood-based, real-time molecular snapshot of cancer-associated signals designed to complement physician-led care, not replace it.

Why It Matters

  • Conventional screening programs only cover a few cancers and are restricted by age or eligibility.
  • Many patients with family history, genetic predisposition, or lifestyle exposures want more comprehensive prevention tools.
  • miRoncol helps bridge this gap with a scientifically validated, ethically grounded test that supports earlier, evidence-informed conversations.

How It Fits Into Family Medicine

Annual checkups

Incorporate real-time cancer risk assessment alongside bloodwork and standard panels.

Preventive counselling

Provide patients with molecular data to guide lifestyle changes and monitoring.

Risk-based referrals

Use results to determine whether additional screening or imaging is appropriate.

See How the Test Works

Scientific Foundation

  • Built on 11,000+ samples across 12+ solid tumour types
  • Specificity above 99%, minimizing false positives
  • Sensitivity >90% for many common cancers
  • Published in Cancers (2022) and Scientific Reports (2024)
Download Publication

Benefits

  • Provides real-time molecular insight beyond standard screening tools
  • Complements established guidelines, offering context for patient-centred care
  • Helps meet patient demand for proactive, preventive health strategies
  • Ethically aligned — designed to support, not replace, diagnostic evaluation

Limitations & Ethics

miRoncol is an early risk assessment tool, not diagnostic. Results should always be interpreted within a clinical context and discussed with patients transparently.

Next Step

By partnering with miRoncol, family doctors and integrative medicine practitioners can offer patients an evidence-based option for enhanced prevention reinforcing trust while supporting informed, physician-led care.

Join the Partner Program Explore Partner Types